The estimated Net Worth of Brian J. Underdown is at least $7.88 Thousand dollars as of 19 March 2021. Brian Underdown owns over 2,500 units of Vistagen Therapeutics stock worth over $7,875 and over the last 8 years he sold VTGN stock worth over $0. In addition, he makes $0 as Independent Director at Vistagen Therapeutics.
Brian has made over 1 trades of the Vistagen Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,500 units of VTGN stock worth $3,750 on 19 March 2021.
The largest trade he's ever made was exercising 2,500 units of Vistagen Therapeutics stock on 19 March 2021 worth over $3,750. On average, Brian trades about 208 units every 0 days since 2016. As of 19 March 2021 he still owns at least 2,500 units of Vistagen Therapeutics stock.
You can see the complete history of Brian Underdown stock trades at the bottom of the page.
Dr. Brian J. Underdown Ph.D. serves as Independent Director of the Company. He has served as a member of our Board of Directors since November 2009, first as a director of VistaGen California, then as a member of our Board after the completion of the Merger. Dr. Underdown retired as a Venture Partner with Lumira Capital Corp.in December 2016, after having served as a Managing Director with Lumira from September 1997 through December 2015. His investment focus has been on therapeutics in both new and established companies in both Canada and the United States. Prior to joining Lumira and its antecedent company MDS Capital Corp., Dr. Underdown held a number of senior management positions in the biopharmaceutical industry and at universities. Dr. Underdown’s current board positions include the following private companies: Kisoji Biotechnology Inc., Naegis Pharmaceuticals, Inc. and Osteo QC. Some of Dr. Underdown’s previous board roles include: Argos Therapeutics (NASDAQ: ARGS), ID Biomedical (acquired by GlaxoSmithKline), enGene Inc. and Ception Therapeutics (acquired by Cephalon). He has served on a number of Boards and advisory bodies of government-sponsored research organizations including CANVAC, the Canadian National Centre of Excellence in Vaccines, Ontario Genomics Institute (Chair), Allergen Plc., the Canadian National Centre of Excellence in Allergy and Asthma. Dr. Underdown obtained his Ph.D. in immunology from McGill University and undertook post-doctoral studies at Washington University School of Medicine.
Brian Underdown is 79, he's been the Independent Director of Vistagen Therapeutics since 2011. There are 1 older and 14 younger executives at Vistagen Therapeutics. The oldest executive at Vistagen Therapeutics Inc. is Jon Saxe, 84, who is the Independent Chairman of the Board.
Brian's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore, and Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Vistagen Therapeutics executives and other stock owners filed with the SEC include: